

Appendix from Preston et al., “An international physician survey of pulmonary arterial hypertension management” (Pulm. Circ., vol. 6, no. 3, p. 338)




Figure S1. Setting of PAH diagnosis (patient record data). Responses to the study question “Which of the provided facility types best describes where this patient received his/her PAH diagnosis?” ^aIn Argentina or Japan, an institution with a department specialized in PH treatment. AR: Argentina; EU: Europe; JP: Japan; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; US: United States.




Figure S2. Combination therapies by setting (patient record data). Based on responses to the study questions “Do you personally work within a PH center of excellence (EU/US)/in an institution with a department specialized in PH treatment (AR/JP)?” and “Please select from the options provided which PAH-specific drugs this patient is currently receiving.” AR: Argentina; EU: Europe; JP: Japan; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; US: United States.




Figure S3. Concomitant medication (patient record data). Responses to the study question “Please indicate whether this patient is currently taking any concomitant medication besides PAH-specific drug therapy. Select all that apply to this patient.” ACE: angiotensin-converting enzyme; AR: Argentina; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; EU: Europe; JP: Japan; PAH: pulmonary arterial hypertension; US: United States.

Table S1. Treatment rate (physician perception data)

	UK (n = 50)	FR (n = 53)	DE (n = 63)	IT (n = 58)	ES (n = 54)	US (n = 160)	AR (n = 53)	JP (n = 69)
No. of patients personally managed	37.0 (13.8)	37.5 (16.8)	34.7 (11.1)	25.9 (6.9)	23.6 (6.4)	57.9 (16.2)	7.1 (2.3)	7.5 (1.7)
No. of patients currently receiving PAH-specific therapy	28.0 (13.0)	33.6 (16.6)	27.9 (8.9)	21.7 (6.0)	19.5 (5.4)	49.3 (15.0)	5.6 (1.5)	6.4 (1.1)
Treatment rate, %	76	89	80	84	83	85	79	85

Note: Responses to the study questions “How many individual PH patients are you currently managing?” and “How many of the PAH patients that are currently under your direct care, are currently treated with PAH-specific drug therapy?” Unless otherwise indicated, data are mean (SEM). AR: Argentina; DE: Germany; ES: Spain; FR: France; IT: Italy; JP: Japan; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; SEM: standard error of the mean; UK: United Kingdom; US: United States.